SCHEDULE 13G/A: ARK Investment Management and Catherine Wood Disclose 2.9% Stake in Adaptive Biotechnologies

ARK Investment Management LLC and its CEO Catherine D. Wood have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Adaptive Biotechnologies Corporation's common stock as of May 31, 2025.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 1 to Schedule 13G regarding their ownership in Adaptive Biotechnologies Corporation.
• As of May 31, 2025, the reporting persons beneficially own 4,398,669 shares of Adaptive Biotechnologies Corporation's Common Stock.
• This ownership represents 2.9% of the total class of securities.
• ARK Investment Management LLC holds sole voting and dispositive power over all 4,398,669 shares.
• Catherine D. Wood holds shared voting and dispositive power over the same 4,398,669 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, non-activist investment by a reputable firm, which can be viewed positively as a vote of confidence. However, it contains no operational or financial news about the company itself.

Positives

• The filing indicates a significant investment by a prominent investment firm, ARK Investment Management LLC, and its well-known CEO, Catherine D. Wood, in Adaptive Biotechnologies Corporation.
• The certification that shares are held in the ordinary course of business suggests a long-term investment strategy rather than an activist intent.

Negatives

• The document itself does not contain negative financial or operational information about Adaptive Biotechnologies Corporation, as it is a disclosure of ownership.

Risks

• The document does not explicitly mention risks related to Adaptive Biotechnologies Corporation's operations or financial health, as it is a beneficial ownership filing.

Future Outlook

This Schedule 13G filing does not provide forward-looking statements or guidance from Adaptive Biotechnologies Corporation. It solely reports the beneficial ownership stake of ARK Investment Management LLC and Catherine D. Wood.

Management Comments

• The document includes a certification from ARK Investment Management LLC and Catherine D. Wood stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing indicates continued or new investment interest from a prominent asset manager, ARK Investment Management, known for its focus on disruptive innovation, particularly in the biotechnology and healthcare sectors. Adaptive Biotechnologies operates in the biotechnology space, aligning with ARK's investment themes. Such a disclosure can signal confidence from a major investor in the company's long-term prospects within its industry.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership below 5%. It does not contain financial performance data for Adaptive Biotechnologies Corporation that would allow for direct comparison to industry standards or specific comparable companies/projects. The 2.9% stake is a specific ownership percentage, not a performance metric.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by ARK Investment Management and Catherine D. Wood may be perceived as a positive signal, potentially influencing investor sentiment and stock price.
• Management: Awareness of a notable institutional investor holding a significant stake may influence management's strategic considerations, though the filing states no intent to influence control.

Next Steps

• The document does not specify any future actions or milestones for Adaptive Biotechnologies Corporation or the reporting persons beyond the regulatory filing itself. Future filings would occur if ownership changes significantly.

Key Dates

Keywords

Adaptive Biotechnologies Corporation, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, SEC Filing